Abstract: A device is provided for pooling a fluid from a container unit having at least one container, and includes an inlet port having at least one inlet channel configured for receiving the fluid or ambient air, and an outlet port having at least one outlet channel configured for delivering the fluid to an attachment. Both inlet and outlet ports are disposed on the device. A cavity is provided for accommodating insertion of the container unit for pooling the fluid from the at least one container. At least one spike is disposed in the cavity and configured for puncturing a stopper of the at least one container when the container unit transitions from an upper position to a lower position.
Type:
Grant
Filed:
January 17, 2020
Date of Patent:
June 27, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Mark David Schweiss, Daniel Edward Roush, Stefan Holzner, Seth Dale Jones, Tejas Dhyani, Michelle Shah, Madeleine Clare Gibson, Jessica Chung, Anthony Martin Looper
Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., ?-galactosidase A (?-Gal A), glucocerebrosidase (GCB), ?-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.
Type:
Grant
Filed:
March 5, 2019
Date of Patent:
June 27, 2023
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Brian Dwyer, Bohong Zhang, Jun Hu, Muthuraman Meiyappan, Thomas Miller, Paul McLean, Clark Pan
Abstract: A method for producing a compound represented by the formula (X): or a salt thereof and has a MALT1 inhibitory action, the said method containing a step for producing a compound a compound represented by the formula (B-2): or a salt thereof and being characterized by comprising crystallizing a salt of a compound represented by the formula (B-1) and an optically active organic acid. (In the formulae, each symbol is as defined in the specification.
Abstract: Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.
Abstract: Systems and devices described herein include multi-dose injection systems for delivering drugs, hormones, biologics, and other therapeutic agents. Systems include multiple single-injection needle connectors attachable to a reusable injector. The needle connectors include a needle having a distal end for administering the therapeutic agent to the patient and a proximal end to pierce a septum of the reusable injector. The proximal ends of the needles across the multiple needle connectors can vary such that the piercing location on the septum varies. The systems also include modular needle connectors. The modular needle connectors can include a disk rotatable within a connector body. A position of a needle within the rotatable disk changes each time the modular needle connector is connected to a reusable injector.
Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.
Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
Abstract: Provided herein are methods for treating acute respiratory distress syndrome (ARDS), such as ARDS associated with respiratory virus infection, involving administering an inhibitor of the contact activation pathway. Also provided herein are methods for treating pneumonia and methods for reducing and/or preventing thrombosis associated with extracorporeal membrane oxygenation (ECMO) in a subject having acute respiratory distress syndrome (ARDS), involving administering an inhibitor of the contact activation pathway.
Type:
Application
Filed:
April 2, 2021
Publication date:
June 8, 2023
Applicant:
Takeda Pharmaceutical Company Limited
Inventors:
Daniel J. Sexton, Neil Inhaber, Giorgio Giannattasio, Donatello Crocetta
Abstract: Systems and methods for providing a clotting factor VIII (CFVIII) dosing regimen include collecting two blood samples from a patient after an infusion of CFVIII and determining a CFVIII clearance based on the two blood samples, and determining if a patient has a half-life greater than a predetermined threshold. A pharmacokinetic (PK) profile of the patient is determined using a Bayesian model of pharmacokinetic profiles of sampled patients having similar body weight or age of the patient. A first weight is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is greater than the predetermined threshold, and a second weight, less than the first weight, is applied to the Bayesian model of pharmacokinetic profiles of sampled patients if the half-life of the patient is less than the predetermined threshold. A dosing regimen is determined for the patient based on the PK profile.
Type:
Grant
Filed:
April 13, 2017
Date of Patent:
June 6, 2023
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
June 6, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
Abstract: GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
May 30, 2023
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Clark Pan, Angela Norton, Bettina Strack-Logue, Clément Olivier
Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
Type:
Grant
Filed:
December 16, 2014
Date of Patent:
May 30, 2023
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
Abstract: The following are disclosed: a method for producing a T cell progenitor, including step (1) of culturing CD34+ cell in a medium containing an aryl hydrocarbon receptor antagonist, a medium for T cell progenitor differentiation containing an aryl hydrocarbon receptor antagonist, and a T cell progenitor inducer containing an aryl hydrocarbon receptor antagonist.
Type:
Application
Filed:
March 30, 2021
Publication date:
May 25, 2023
Applicants:
Kyoto University, TAKEDA PHARMACEUTICAL COMPANY LIMITED
Abstract: The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof.
Type:
Grant
Filed:
March 21, 2017
Date of Patent:
May 23, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Venkata R. Garigapati, Tetsuo Hoshino, Amit Garle
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.